Lilly taps Haya for weight-loss collaboration

Sep 9, 2024 · The most valuable pharmaceutical company in the world has tapped Swiss biotech Haya Therapeutics to develop weight-loss drugs that target a specific type of RNA. Eli Lilly and …

CouponFollow Extension

$1
OFF

Lilly Lays Down $1B To Be ‘first In Biology’ With Obesity Gene ...

4 weeks from now

Sep 9, 2024 · Last week, Lilly struck a deal with Haya Therapeutics, a Switzerland and San Diego-based biotech in the early phases of lncRNA development targeting chronic diseases. …

pharmavoice.com

$1
OFF

Lilly Taps Haya In $1B Deal To Tackle 'dark Genome' For New Obesity …

4 weeks from now

Sep 4, 2024 · Eli Lilly, fresh off the blockbuster success of its weight-loss injection Zepbound (tirzepatide), is teaming up with Haya Therapeutics in a multi-year deal to explore the so-called …

firstwordpharma.com

$1
OFF

Lilly Partners With Haya For LncRNA Obesity Target Deal Worth $1bn

4 weeks from now

Sep 5, 2024 · Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in …

pharmaceutical-technology.com

$1
OFF

Lilly, Haya Ink Potential $1B Drug Discovery Deal To Target

4 weeks from now

Sep 4, 2024 · Eli Lilly is diving further into the obesity space with a potential billion-dollar deal with Haya Therapeutics. The companies announced a collaboration Wednesday to utilize the Swiss …

biospace.com

$1
OFF

Lilly To Hunt Non-coding DNA For Obesity Drugs In $1bn Deal

4 weeks from now

6 days ago · The partnership with Haya is further evidence of Lilly's intention to build on Zepbound, with new treatment modalities that could deliver new and complementary ways to …

pharmaphorum.com

$1
OFF

HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration

4 weeks from now

Sep 4, 2024 · Lilly has agreed to pay HAYA an undisclosed upfront payment, including an equity investment, as well as up to $1 billion in payments tied to achieving preclinical, clinical, and …

genengnews.com

$1
OFF

Eli Lilly And HAYA Therapeutics Enter Metabolic Condition …

4 weeks from now

Sep 6, 2024 · Eli Lilly and HAYA Therapeutics have entered into a multi-year agreement worth up $1bn to discover regulatory genome targets for obesity and related metabolic conditions. The …

pmlive.com

98%
OFF

HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration

4 weeks from now

Sep 4, 2024 · Samir Ounzain, PhD, co-founder and CEO of HAYA Therapeutics. The noncoding portion that makes up 98% of the human genome is anything but “junk” to HAYA Therapeutics, …

sdbn.org

$1
OFF

Eli Lilly Inks $1B Partnership With San Diego Biotech

4 weeks from now

Sep 10, 2024 · SAN DIEGO – HAYA Therapeutics, a 35-person biotech company with presence in Switzerland and San Diego, has entered a collaboration agreement with Eli Lilly and …

sdbj.com

FAQs about Lilly taps Haya for weight-loss collaboration Coupon?

Will Eli Lilly and Haya Therapeutics find RNA-based drug targets for obesity?

Eli Lilly and Haya Therapeutics aim to find multiple regulatory genome derived RNA-based drug targets for obesity. Credit: eamesBot via Shutterstock. Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in obesity. ...

Is Haya a 'junk' to Eli Lilly?

The noncoding portion that makes up 98% of the human genome is anything but “junk” to HAYA Therapeutics, which said it is partnering with Eli Lilly to identify multiple regulatory genome-derived RNA-based drug targets for obesity and related metabolic conditions through a collaboration that could generate up to $1 billion for the Swiss biotech. ...

Could Haya get $1bn from Eli Lilly?

Haya could secure up to $1bn after hitting preclinical, clinical, and commercial milestones with drugs that emerge from this deal. Eli Lilly and Haya Therapeutics aim to find multiple regulatory genome derived RNA-based drug targets for obesity. Credit: eamesBot via Shutterstock. ...

Does Lilly have a target for obesity?

It comes as no surprise that Lilly is eyeing up new targets in obesity, as it is one of the frontrunners in the space. Its blockbuster drug tirzepatide, which is marketed as Mounjaro for type 2 diabetes and Zepbound for obesity is the main competitor for Novo Nordisk ’s semaglutide versions, Ozempic and Wegovy. ...

Will Lilly pay Haya a $1 billion lncRNA investment?

Lilly has agreed to pay HAYA an undisclosed upfront payment, including an equity investment, as well as up to $1 billion in payments tied to achieving preclinical, clinical, and commercial milestones, plus royalties on product sales. Lilly is the second big-name biopharma to invest in an lncRNA collaboration in as many weeks. ...

Does Eli Lilly have a pact with Chinese biotech?

Eli Lilly in pact with Chinese biotech for novel weight loss therapy Nov. 20, 2024 2:28 PM ETEli Lilly and Company (LLY) StockABy: Dulan Lokuwithana, SA News Editor12 Comments Play(1min) jetcityimage/iStock Editorial via Getty Images ...